Fanconi anemia is a rare recessive disorder characterized by genome instability, congenital malformations, progressive bone marrow failure and predisposition to hematologic malignancies and solid tumors 1 . At the cellular level, hypersensitivity to DNA interstrand crosslinks is the defining feature in Fanconi anemia 2 . Mutations in thirteen distinct Fanconi anemia genes 3 have been shown to interfere with the DNA-replication-dependent repair of lesions involving crosslinked DNA at stalled replication forks 4 . Depletion of SLX4, which interacts with multiple nucleases and has been recently identified as a Holliday junction resolvase 5-7 , results in increased sensitivity of the cells to DNA crosslinking agents. Here we report the identification of biallelic SLX4 mutations in two individuals with typical clinical features of Fanconi anemia and show that the cellular defects in these individuals' cells are complemented by wildtype SLX4, demonstrating that biallelic mutations in SLX4 (renamed here as FANCP) cause a new subtype of Fanconi anemia, Fanconi anemia-P.
Fanconi anemia is a rare recessive disorder characterized by genome instability, congenital malformations, progressive bone marrow failure and predisposition to hematologic malignancies and solid tumors 1 . At the cellular level, hypersensitivity to DNA interstrand crosslinks is the defining feature in Fanconi anemia 2 . Mutations in thirteen distinct Fanconi anemia genes 3 have been shown to interfere with the DNA-replication-dependent repair of lesions involving crosslinked DNA at stalled replication forks 4 . Depletion of SLX4, which interacts with multiple nucleases and has been recently identified as a Holliday junction resolvase [5] [6] [7] , results in increased sensitivity of the cells to DNA crosslinking agents. Here we report the identification of biallelic SLX4 mutations in two individuals with typical clinical features of Fanconi anemia and show that the cellular defects in these individuals' cells are complemented by wildtype SLX4, demonstrating that biallelic mutations in SLX4 (renamed here as FANCP) cause a new subtype of Fanconi anemia, Fanconi anemia-P.
SLX4 is a multidomain scaffold protein that interacts with three distinct nucleases: SLX1, ERCC4/XPF-ERCC1 and MUS81-EME1 [5] [6] [7] . Although the SLX4-SLX1 interaction is largely responsible for the Holliday junction resolvase activity seen in the complex, SLX4 can also stimulate the activity of ERCC4/XPF and MUS81 nucleases, both of which have been previously implicated in the processing of interstrand crosslinks (ICLs) 8 . The finding that depletion of SLX4 leads to increased sensitivity to crosslinking agents and to camptothecin [5] [6] [7] prompted us to investigate SLX4 as a candidate gene for Fanconi anemia 1, 2 .
So far, mutations in thirteen genes have been shown to be responsible for Fanconi anemia 3 . Eight of the Fanconi anemia proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL and FANCM) form a core complex, a nuclear E3 ubiquitin ligase which ubiquitinates FANCI and FANCD2 (refs. 9,10). These two activated proteins subsequently localize as an FANCI-FANCD2 complex to chromatin and direct repair 4 partly through interaction with the newly identified nuclease FAN1 (refs. 11-14) . Cells with mutations in the Fanconi anemia core complex (except for FANCM) lack monoubiquitination of FANCD2. The other Fanconi anemia proteins are FANCJ (also known as BRIP1), a helicase, and the homologous recombination effectors FANCN (also known as PALB2) and FANCD1 (also known as BRCA2). Recently, RAD51C, also involved in homologous recombination repair, has been found to be mutated in three individuals with a Fanconi anemia-like disorder 15 . Cells mutated in FANCJ (BRIP1), FANCN (PALB2), FANCD1 (BRCA2) and RAD51C have normal FANCD2 monoubiquitination, and their products are thought to work downstream of the FANCI-FANCD2 complex.
As depletion of SLX4 in a U2OS cell line does not affect FANCD2 ubiquitination ( Fig. 1a,b) , we sequenced SLX4 in the families from the International Fanconi Anemia Registry 16 with unassigned Fanconi anemia complementation groups and normal FANCD2 modification ( Fig. 1c ) and identified two families carrying germline mutations, IFAR1084 and IFAR414 ( Fig. 1d) . Phenotypes of the two affected individuals are summarized in Table 1 . The lymphoblastoid cell line (LCL) (RA3042) and fibroblasts (RA3083) from individual 1084/1 showed increased genomic instability ( Fig. 1e and Table 2 ) and increased sensitivity to mitomycin C (MMC) ( Supplementary  Fig. 1a ). The 414/1 individual's LCL (RA 1376) was not sensitive to MMC, suggestive of reversion ( Supplementary Fig. 1b) ; however, his skin fibroblasts (RA 3331) displayed a high degree of diepoxybutane (DEB)-induced chromosomal instability ( Fig. 1e and Table 2 ) and sensitivity to MMC. We observed no ultraviolet sensitivity in fibroblasts from either of the affected individuals ( Supplementary  Fig. 1c,d) . Fibroblasts from individual 414/1 (RA3331) but, interestingly, not individual 1084/1 (RA3083) were sensitive to camptothecin, a topoisomerase I inhibitor ( Supplementary Fig. 1e,f) .
Sequencing of the complementary DNA (cDNA) from the 1084/1 individual's cells revealed skipping of exon 5 (Supplementary Fig. 2a ) due to a homozygous point mutation in the canonical splice donor dinucleotide GT in intron 5 (c.1163+2T>A) in the genomic DNA ( Supplementary Fig. 2b ). We found both of this individual's parents to be heterozygous and found an unaffected sibling to be negative for this mutation (Supplementary Fig. 2b) . The predicted effect of this mutation is a 70-amino-acid deletion of amino acids 317-387 of SLX4 (p.Arg317_Phe387del) leading to an in-frame deletion of the conserved cysteine and leucine of the first UBZ domain and the whole second UBZ domain ( Fig. 2a and Supplementary Fig. 2c ). Supplementary Fig. 2d ).
Mutations of the SLX4 gene in Fanconi anemia
In individual 414/1, we detected a heterozygous frameshift mutation in exon 2 (c.514delC) by sequencing of the full length RT-PCR product (Supplementary Fig. 3a ) and confirmed it in the genomic DNA of this individual and his father ( Supplementary Fig. 3b ). The predicted protein effect of this frameshift mutation is a truncated protein with N-terminal 171 amino acids of SLX4 followed by 22 non-SLX4 amino acids (p.Leu172PhefsX22) ( Fig. 2a) . The second allele of SLX4 in the individual 414/1, identified as described in the Online Methods, showed a large genomic deletion from intron 9 to exon 12 resulting in c.2013+225_3147delinsCC ( Supplementary  Fig. 3c-e ). The predicted effect of this mutation is a truncated protein with N-terminal 671 amino acids of SLX4 followed by 119 non-SLX4 amino acids due to a frameshift (p.Leu672ValfsX119) ( Fig. 2a) . Consequently, immunoprecipitation with the antibody against SLX4 failed to identify the full-length protein in the individual's fibroblasts (RA3331) ( Fig. 2b lane 6) .
To prove that the mutations identified in SLX4 were causal for the Fanconi anemia phenotype of both affected individuals, we introduced the wildtype or the mutant SLX4 cDNAs into these individuals' fibroblasts (RA3083 and RA3331) and performed functional complementation assays ( Fig. 3 and Supplementary Fig. 4 ). Expression of wild-type SLX4 in both cell lines almost fully rescued the MMC sensitivity ( Fig. 3a and Supplementary Fig. 4a,b) , the late S/G2 arrest with MMC treatment ( Fig. 3b and Supplementary Fig. 4c-e ) and the chromosomal instability after treatment with DEB ( Supplementary  Fig. 4f ). Some residual MMC sensitivity, cell cycle arrest and chromosomal breakage is most likely due to some cells losing expression of SLX4, as evident by immunofluorescence analysis (data not shown). Introduction of the mutant proteins did not rescue the Fanconi anemia phenotypes of these individuals' cells, although we noted a slight improvement in the various assays, possibly due to overexpression of the mutant proteins, which might have residual function. These experiments demonstrate that biallelic SLX4 mutations cause a new subtype of Fanconi anemia, Fanconi anemia-P, and that FANCP becomes an alias for SLX4.
SLX4 interacts with multiple factors; two of which, ERCC4/XPF and MUS81, have been previously implicated in crosslink repair 8 . We therefore tested whether the mutant SLX4 proteins from both affected individuals still interacted with the ERCC4/XPF and MUS81 complexes. We found that ERCC4/XPF, MUS81 and ERCC1 coimmunoprecipitated with endogenous mutant SLX4 (p.Arg317_Phe387del) from RA3083 fibroblasts ( Fig. 4a lane 5 and Supplementary Fig. 5a lane 4) , although the levels of the mutant SLX4 protein were consistently lower in multiple experiments, leading to diminished immunoprecipitation of the interacting factors. The SLX4 p.Leu672ValfsX119 mutant protein, overexpressed in RA3331 fibroblasts, showed diminished but present interaction with ERCC4/XPF Fig. 4b lane 3 ). This result is consistent with the previous findings that MUS81 interacts with the amino acid 684-1,834 fragment of the SLX4 protein 7 , which is deleted in the p.Leu672ValfsX119 mutant protein. Immunoprecipitation with an antibody recognizing the N terminus of SLX4 from RA3331 cells showed greatly diminished interaction with ERCC4/XPF, ERCC1 and MUS81 (Supplementary Fig. 5b lane 6) .
As UBZ domains are known to interact with ubiquitin 17 , we hypothesized that the absence of the tandem UBZ domains in the mutant SLX4 from individual 1084/1 might disrupt the binding of the SLX4 complex to ubiquitin chains of repair proteins at the sites of DNA damage, as shown for the tandem UBZ domains of RAP80 (ref. 18) . We therefore performed in vitro ubiquitin binding assays (Fig. 4c) that showed binding of the isolated UBZ domains of SLX4 to the K63 chains of ubiquitin ( Fig. 4c lane 8) . When the two conserved cysteines from each UBZ domain were mutated to alanines (Supplementary Fig. 2c) , the binding was reduced to background levels seen with GST alone (Fig. 4c, compare lane 7 and 9 ), suggesting the possibility that SLX4 may localize to the sites of damage through binding to K63 ubiquitinated substrates. As SLX4 would localize other proteins, including ERCC4/XPF, MUS81 and SLX1, to sites of DNA damage, the SLX4deficient cell lines described here are important tools to understand which interactions of SLX4 are essential for the repair of cross-linked DNA and ultimately to define the importance of the SLX4 (FANCP) function in the Fanconi anemia pathway. Phenotypes of the affected individuals also provide an important clue. Individuals with Fanconi anemia with mutations in PALB2 (FANCN) or BRCA2 (FANCD1), which are essential for homologous recombination, have very early onset of childhood solid tumors and acute myelogenous leukemia 19, 20 . l e t t e r s Individuals with Fanconi anemia having SLX4 (FANCP) mutations show a milder phenotype more akin to that seen in individuals with mutations in the Fanconi anemia core or the FANCI-FANCD2 complex components. This suggests that the Holliday junction resolution, an integral step of homologous recombination, might not be the essential function of SLX4 in the somatic compartment during crosslink repair and that the repair depends on the other nucleases, ERCC4/XPF and MUS81, that interact with SLX4. SLX4 (FANCP) represents a second protein (besides FANCM) that is conserved in lower eukaryotes, which do not have any other Fanconi anemia pathway components. Yeast Slx4, like human SLX4, interacts with orthologs of ERCC4/XPF and SLX1, and the work in this model organism will provide insight into the function of the Fanconi anemia pathway in human cells. Because germ-line mutations in three Fanconi anemia genes (BRCA1 (FANCD1), PALB2 (FANCN) and BRIP1 (FANCJ)) and RAD51C, mutated in an Fanconi anemia-like disorder, are associated with a high risk of developing familial breast and ovarian cancers [21] [22] [23] [24] , SLX4 should also be sequenced in individuals from pedigrees where no other predisposing mutations could be identified.
MetHoDS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Figure 4 Interaction of mutant forms of SLX4 with its partners and with ubiquitin. (a) Analysis of SLX4-interacting partners in SLX4 mutant cells. We subjected cell extracts of primary fibroblasts (BJ, RA3083 and RA3331) to immunoprecipitation using the SLX4 antibody. We identified interacting proteins by immunoblotting with the indicated antibodies. (b) Analysis of SLX4-interacting partners in RA3331 cells. We subjected cell extracts of RA3331 E6E7 cells expressing HA-tagged control vector, wild-type SLX4 or the p.Leu672ValfsX119 SLX4 alteration to immunoprecipitation using HA antibody or HA antibody in the presence of 30 µg of HA peptide. We identified interacting proteins by immunoblotting with the indicated antibodies. Table 1 ). Genomic PCR was done using QIAGEN Taq Polymerase with primers shown in Supplementary Table 1 . The PCR products were cleaned up using the USB Exo-Sapit kit before being set up for sequencing. In most cases, the PCR primers were also suitable for sequencing.
Identification of the second allele in IFAR414/1. In order to identify the second allele in the RA3331 cell line, full genomic sequencing of the coding exons was done on the subject's and the maternal DNA. A genomic deletion was found to be likely based on informative polymorphic markers in exon 12: c.3162G>A (p.Ser1054Ser, rs76488917) and c.3365C>T (p.Pro1122Leu, rs714181). Amplification of parts of the cDNA followed by a detailed sequence analysis revealed retention of IVS9 through c.2013+224, with deletion of c.2013+225_3147 and insertion of two cytosine nucleotides in its place: hence c.2013+225_3147del4890insCC (Supplementary Fig. 2d ). To confirm this result, a genomic PCR assay was set up using primers flanking the deletion. The resulting wild-type amplicon (6,821 bp) failed to amplify under the PCR conditions we used, but the deleted allele resulted in a 1,931-bp amplicon from the subject's and the mother's DNA but not the father's DNA ( Supplementary  Fig. 3e ). Direct sequencing of the mutant amplicon confirmed the result observed in the cDNA (Supplementary Fig. 3c ). The sequencing result appears homozygous because the wildtype allele did not amplify.
Plasmids. The wild-type SLX4 cDNA was a kind gift from the Harper Lab, Harvard Medical School, Boston, Massachusetts, USA. Mutant alleles were amplified and recombined into pDONR223 (ref. 25). pDONR223 derivatives were recombined into pHAGE vectors or pDEST15 using LR clonase (Invitrogen). HPV16 E6E7 genes (gift from Howley Lab, Harvard Medical School, Boston, Massachusetts, USA) were subcloned into pMSCVneo (Clontech) and used to transform the primary cells. pWZLhTERT 26 was used to immortalize RA3083 and BJ cell lines.
